{"filing":{"accession_number":"0001745114-26-000028","cik":"0001745114","ticker":"MOLN","company_name":"MOLECULAR PARTNERS AG","form":"6-K","filing_date":"2026-08-25","report_date":"2026-06-30","primary_document":"moln-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745114/000174511426000028/moln-20260630.htm"},"events":[{"id":29283,"run_id":26797,"accession_number":"0001745114-26-000028","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release disclosing H1 2026 financial results for Molecular Partners AG, including operating loss of CHF 27.0 million, net loss of CHF 26.7 million, cash position of CHF 67.9 million, and cash runway into late 2027. The document explicitly states \"Molecular Partners Reports H1 2026 Financial Results\" and includes a financial table with key metrics (revenues, R\u0026D expenses, operating expenses, net result, cash flow, and shareholders' equity). While the release also covers pipeline progress and corporate governance, the primary disclosure is the interim financial results, which is material to investor assessment of the company's financial condition and runway.","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-08-25","form":"6-K","submitted_at":null,"items":[{"id":31509,"accession_number":"0001745114-26-000028","item_number":"EX-99.1","item_title":"mpprh12026sec.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release disclosing H1 2026 financial results for Molecular Partners AG, including operating loss of CHF 27.0 million, net loss of CHF 26.7 million, cash position of CHF 67.9 million, and cash runway into late 2027. The document explicitly states \"Molecular Partners Reports H1 2026 Financial Results\" and includes a financial table with key metrics (revenues, R\u0026D expenses, operating expenses, net result, cash flow, and shareholders' equity). While the release also covers pipeline progress and corporate governance, the primary disclosure is the interim financial results, which is material to investor assessment of the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-25T10:09:41.257705+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31509,"accession_number":"0001745114-26-000028","item_number":"EX-99.1","item_title":"mpprh12026sec.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release disclosing H1 2026 financial results for Molecular Partners AG, including operating loss of CHF 27.0 million, net loss of CHF 26.7 million, cash position of CHF 67.9 million, and cash runway into late 2027. The document explicitly states \"Molecular Partners Reports H1 2026 Financial Results\" and includes a financial table with key metrics (revenues, R\u0026D expenses, operating expenses, net result, cash flow, and shareholders' equity). While the release also covers pipeline progress and corporate governance, the primary disclosure is the interim financial results, which is material to investor assessment of the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-25T10:09:41.257705+00:00","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-08-25"}]}